LOS ANGELES — Newer glucose-lowering drugs reduce the risk for late-onset seizures and epilepsy by 24%, with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) cutting the risk by 33%, according to a new meta-analysis.

Glucagon-like peptide 1 (GLP-1) medications have become a powerful weight loss tool in a country where 40% of the population is obese. Patients taking these medications can experience weight loss, a life changing amount for those who have been struggling with weight and related health problems for much of their lives.

Aerobic exercise shows a linear relationship with weight loss, with 30 minutes of weekly exercise linked to reduced body weight, waist circumference, and body fat in adults who were overweight or had obesity.

Combined exposure to dioxins and dioxin-like polychlorinated biphenyls (DL-PCBs) is significantly associated with an increased risk for obesity in adults, with 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD) showing the greatest contribution.

Hi. I'm Tamaan K. Osbourne-Roberts, family medicine physician and lifestyle medicine physician, here to discuss GLP-1 receptor agonist (RA) contraindications — the skinny on when not to prescribe.

About 20% of adolescents have obesity, a figure that is expected to rise over the next few decades. And while popular weight loss drugs are a potential tool for physicians caring for these young people, many doctors are not yet sure that these drugs are ready to be front-line treatments.

Objectives: This research surveyed Tier 3 adult weight management services in England commissioned by integrated care boards (ICBs) across England in financial year 2022-2023.